Susquehanna International Group’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-185,800
Closed -$424K 13317
2024
Q2
$424K Buy
185,800
+48,700
+36% +$186K ﹤0.01% 8680
2024
Q1
$592K Buy
137,100
+46,200
+51% +$161K ﹤0.01% 8094
2023
Q4
$277K Buy
90,900
+56,000
+160% +$105K ﹤0.01% 9985
2023
Q3
$50.3K Sell
34,900
-23,700
-40% -$45.9K ﹤0.01% 11305
2023
Q2
$146K Buy
58,600
+31,900
+119% +$87.1K ﹤0.01% 10607
2023
Q1
$71.6K Sell
26,700
-10,900
-29% -$52.4K ﹤0.01% 11519
2022
Q4
$204K Buy
37,600
+9,000
+31% +$75.4K ﹤0.01% 10073
2022
Q3
$357K Buy
28,600
+10,900
+62% +$125K ﹤0.01% 9358
2022
Q2
$87K Sell
17,700
-18,800
-52% -$104K ﹤0.01% 11597
2022
Q1
$277K Sell
36,500
-2,100
-5% -$19.9K ﹤0.01% 10470
2021
Q4
$394K Sell
38,600
-5,300
-12% -$67.5K ﹤0.01% 9826
2021
Q3
$589K Sell
43,900
-70,000
-61% -$1.14M ﹤0.01% 8951
2021
Q2
$2.5M Sell
113,900
-202,200
-64% -$4.49M ﹤0.01% 5417
2021
Q1
$7.61M Buy
316,100
+105,800
+50% +$2.46M ﹤0.01% 3217
2020
Q4
$3.78M Buy
210,300
+182,200
+648% +$2.72M ﹤0.01% 3915
2020
Q3
$325K Buy
28,100
+17,000
+153% +$281K ﹤0.01% 8545
2020
Q2
$269K Buy
+11,100
New +$184K ﹤0.01% 8544
2020
Q1
Sell
-12,500
Closed -$330K 11041
2019
Q4
$330K Sell
12,500
-14,000
-53% -$327K ﹤0.01% 7844
2019
Q3
$604K Buy
26,500
+18,500
+231% +$583K ﹤0.01% 6856
2019
Q2
$245K Sell
8,000
-2,700
-25% -$56.8K ﹤0.01% 8715
2019
Q1
$178K Buy
+10,700
New +$203K ﹤0.01% 7943
2018
Q4
Sell
-12,900
Closed -$675K 10173
2018
Q3
$675K Buy
+12,900
New +$703K ﹤0.01% 5994

Susquehanna International Group's GTHX Position: Q2 2024 in Review

Susquehanna International Group sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q2 2024, closing a stake of 950,839 shares — an estimated $3.63M sold.

Susquehanna International Group first reported a position in GTHX in Q2 2019 and held it in 19 quarters. The position peaked at $4.81M in Q4 2023. 88 funds tracked by Wall St. Rank hold GTHX as of Q2 2024.

  • Susquehanna International Group reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Susquehanna International Group sold 950,839 G1 Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $3.63M.
  • Susquehanna International Group first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2019 and held it in 19 quarters.
  • Susquehanna International Group's G1 Therapeutics, Inc. Common Stock position peaked at $4.81M in Q4 2023.
  • 88 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Susquehanna International Group's 13F filing for Q2 2024, filed 15 Aug 2024.